Table of Contents Author Guidelines Submit a Manuscript
Journal of Healthcare Engineering
Volume 4 (2013), Issue 1, Pages 47-66
Research Article

Low Probability Activation of Bax/Bak Can Induce Selective Killing of Cancer Cells by Generating Heterogeneity in Apoptosis

Subhadip Raychaudhuri1 and Somkanya C. Das2,3

1Department of Chemistry, University of California, Davis, California, USA
2Genome Center, University of California, Davis, California, USA
3Department of Biomedical Engineering, University of California, Davis, California, USA

Received 1 July 2012; Accepted 1 November 2012

Copyright © 2013 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Letai, M. C. Bassik, L. D. Walensky, M. D. Sorcinelli, S. Weiler, and S. J. Korsmeyer, “Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics,” Cancer Cell, vol. 2, pp. 183–192, 2002. View at Google Scholar
  2. A. Letai, “BH3 Domains as BCL-2 Inhibitors: Prototypes Cancer Therapeutics,” Expert Opinion Biol Ther, vol. 3, pp. 293–304, 2003. View at Google Scholar
  3. A. Letai, M. D. Sorcinelli, C. Beard, and S. J. Korsmeyer, “Antiapoptotic BCL-2 is required for maintenance of a model leukemia,” Cancer Cell, vol. 6, pp. 241–249, 2004. View at Google Scholar
  4. T. N. Chonghaile and A. Letai, “Mimicking the BH3 domain to kill cancer cells,” Oncogene, Suppl 1, pp. S149–157, 2008. View at Google Scholar
  5. V. Labi, F. Grespi, F. Baumgartner, and A. Villunger, “Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?” Cell Death Differ, vol. 15, pp. 977–987, 2008. View at Google Scholar
  6. J. L. Wang, D. Liu, Z. J. Zhang et al., “Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells,” Proc Natl Acad Sci USA, vol. 97, pp. 7124–7129, 2000. View at Google Scholar
  7. J. Skommer, D. Wlodkowic, M. Mättö, M. Eray, and J. Pelkonen, “HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells,” Leuk. Res, vol. 30, pp. 322–331, 2006. View at Google Scholar
  8. F. Manero, F. Gautier, T. Gallenne et al., “The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death,” Cancer Res, vol. 66, pp. 2757–2764, 2006. View at Google Scholar
  9. T. M. Kohl, C. Hellinger, F. Ahmed et al., “BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL-2 in primary AML blasts,” Leukemia, vol. 21, pp. 1763–1772, 2007. View at Google Scholar
  10. L. M. High, B. Szymanska, U. Wilczynska-Kalak et al., “The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs,” Mol. Pharmacol, vol. 77, pp. 483–494, 2010. View at Google Scholar
  11. J. Skommer, T. Brittain, and S. Raychaudhuri, “Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death,” Apoptosis, vol. 15, pp. 1223–1233, 2010. View at Google Scholar
  12. J. Skommer, S. C. Das, A. Nair, T. Brittain, and S. Raychaudhuri, “Nonlinear regulation of commitment to apoptosis by simultaneous inhibition of Bcl-2 and XIAP in leukemia and lymphoma cells,” Apoptosis, vol. 16, pp. 619–626, 2011. View at Google Scholar
  13. M. Certo, V. Del Gaizo Moore, M. Nishino et al., “Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members,” Cancer Cell, vol. 9, pp. 351–65, 2006. View at Google Scholar
  14. V. Del Gaizo Moore and A. Letai, “BH3 profiling—Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions,” Cancer Lett, 2012. View at Publisher · View at Google Scholar
  15. L. D. Walensky, K. Pitter, J. Morash et al., “A stapled BID BH3 helix directly binds and activates BAX,” Mol Cell, vol. 24, pp. 199–210, 2006. View at Google Scholar
  16. J. L. Labelle, S. G. Katz, G. H. Bird et al., “A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers,” J Clin Invest, vol. 122, pp. 2018–31, 2012. View at Google Scholar
  17. C. Bodur and H. Basaga, “Bcl-2 inhibitors: emerging drugs in cancer therapy,” Curr Med Chem, vol. 19, pp. 1804–20, 2012. View at Google Scholar
  18. M. L. Hartman and M. Czyz, “Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy,” Anticancer Agents Med Chem, 2012, (PMID: 22263800). View at Google Scholar
  19. S. L. Khaw, D. C. Huang, and A. W. Roberts, “Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies,” Pathology, vol. 43, pp. 525–35, 2011. View at Google Scholar
  20. W. Fan, Z. Tang, L. Yin et al., “MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents,” Cancer Res, vol. 71, pp. 4494–505, 2011. View at Google Scholar
  21. E. M. Beauchamp and L. C. Platanias, “BH3 mimetics and multi-kinase inhibition in AML,” Blood, vol. 119, pp. 5947–8, 2012. View at Google Scholar
  22. M. Rahmani, M. M. Aust, E. Attkisson, D. C. Williams Jr, A. Ferreira-Gonzalez, and S. Grant, “Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process,” Blood, vol. 119, no. 25, pp. 6089–98, 2012. View at Google Scholar
  23. E. Gavathiotis, D. E. Reyna, J. A. Bellairs, E. S. Leshchiner, and L. D. Walensky, “Direct and selective small-molecule activation of proapoptotic BAX,” Nat Chem Biol, 2012. View at Publisher · View at Google Scholar
  24. M. J. Nyhan, T. R. O'Donovan, B. Elzinga, L. C. Crowley, G. C. O'Sullivan, and S. L. McKenna, “The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells,” Br J Cancer, vol. 106, pp. 711–8, 2012. View at Google Scholar
  25. A. Shamas-Din, H. Brahmbhatt, B. Leber, and DW. Andrews, “BH3-only proteins: Orchestrators of apoptosis,” Biochim Biophys Acta, vol. 1813, pp. 508–20, 2011. View at Google Scholar
  26. C. Grills, D. A. Fennell, and S. F. C. Shearer, “Markov modelling of mitochondrial BAK activation kinetics during apoptosis in,” in SAGA'09 Proceedings of the 5th international conference on Stochastic algorithms: foundations and applications, O. Watanabe and T. Zeugmann, Eds., pp. 191–205, Springer-Verlag, Berlin, Heidelberg, 2009.
  27. R. G. Hawley, Y. Chen, I. Riz, and C. Zeng, “An Integrated Bioinformatics and Computational Biology Approach Identifies New BH3-Only Protein Candidates,” Open Biol J, vol. 5, pp. 6–16, 2012. View at Google Scholar
  28. K. P. Ng, A. M. Hillmer, C. T. Chuah et al., “A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer,” Nat Med, vol. 18, pp. 521–8, 2012. View at Google Scholar
  29. J. Skommer, D. Wlodkowic, and A. Deptala, “Larger than life: Mitochondria and the Bcl-2 family,” Leuk. Res, vol. 31, pp. 277–86, 2007. View at Google Scholar
  30. J. E. Chipuk, T. Moldoveanu, F. Llambi, M. J. Parsons, and D. R. Green, “The BCL-2 Family Reunion,” Molecular Cell, vol. 37, pp. 299–310, 2010. View at Google Scholar
  31. A. M. Petros, E. T. Olejniczak, and S. W. Fesik, “Structural biology of the Bcl-2 family of proteins,” Biochimica et Biophysica Acta, vol. 1644, pp. 83–94, 2004. View at Google Scholar
  32. A. M. Burger, “Targeting Leukemic Stem Cells. Cancer Drug Discovery and Development,” Stem Cells and Cancer, vol. 5, pp. 263–273, 2009. View at Google Scholar
  33. S. Raychaudhuri, E. Willgohs, T. N. Nguyen, E. M. Khan, and T. Goldkorn, “Monte Carlo simulation of cell death signaling predicts large cell-to-cell stochastic fluctuations through the type 2 pathway of apoptosis,” Biophys J, vol. 95, pp. 3559–3562, 2008. View at Google Scholar
  34. S. Raychaudhuri, “Minimal model of a signaling network elucidates cell-to-cell stochastic variability in apoptosis,” PLoS One, vol. 5:e11930, 2010. View at Google Scholar
  35. S. Raychaudhuri, J. Skommer, K. Henty, N. Birch, and T. Brittain, “Neuroglobin protects nerve cells from apoptosis by inhibiting the intrinsic pathway of cell death,” Apoptosis, vol. 15, pp. 401–411, 2010. View at Google Scholar
  36. J. G. Albeck, J. M. Burke, S. L. Spencer, D. A. Lauffenburger, and P. K. Sorger, “Modeling a snap-action, variable-delay switch controlling extrinsic cell death,” PLoS Biol, vol. 6, pp. 2831–2852, 2008. View at Google Scholar
  37. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, pp. 105–111, 2001. View at Google Scholar
  38. C. V. Cox, R. S. Evely, A. Oakhill, D. H. Pamphilon, N. J. Goulden, and A. Blair, “Characterization of acute lymphoblastic leukemia progenitor cells,” Blood, vol. 104, pp. 2919–2925, 2004. View at Google Scholar
  39. J. E. Dick, “Acute myeloid leukemia stem cells,” Ann N Y Acad Sci, vol. 1044, pp. 1–5, 2005. View at Google Scholar
  40. H. Clevers, “The cancer stem cell: premises, promises and challenges,” Nature Med, vol. 17, pp. 313–319, 2011. View at Google Scholar
  41. D. Watters and M. Lavin, Eds., Signaling Pathways in Apoptosis, Hardwood academic publishers, 1999.
  42. L. P. Billen, A. Shamas-Din, and D. W. Andrews, “Bid: a Bax-like BH3 protein,” Oncogene, vol. 27, pp. S93–S104, 2009. View at Google Scholar
  43. L. Cabon, P. Galán-Malo, A. Bouharrour et al., “BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation,” Cell Death and Differ, vol. 19, pp. 245–256, 2012. View at Google Scholar
  44. S. J. Korsmeyer, M. C. Wei, M. Saito, S. Weiler, K. J. Oh, and P. H. Schlesinger, “Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c,” Cell Death and Differ, vol. 7, pp. 1166–1173, 2000. View at Google Scholar
  45. J. M. McDonnell, D. Fushman, C. L. Milliman, S. J. Korsmeyer, and D. Cowburn, “Solution Structure of the Proapoptotic Molecule BID: A Structural Basis for Apoptotic Agonists and Antagonists,” Cell, vol. 96, pp. 625–634, 1999. View at Google Scholar
  46. F. Hua, M. G. Cornejo, M. H. Cardone, C. L. Stokes, and D. A. Lauffenburger, “Effects of Bcl-2 Levels on Fas signaling induced caspase 3 activation: molecular genetic tests of computational model predictions,” J Immunol, vol. 175, pp. 985–995, 2005. View at Google Scholar
  47. J. C. Goldstein, N. J. Waterhouse, P. Juin, G. I. Evan, and D. R. Green, “The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant,” Nat Cell Biol, vol. 2, pp. 156–162, 2000. View at Google Scholar
  48. C. W. Gardiner, Handbook of stochastic methods for Physics, Chemistry and the natural Sciences, Springer-Verlag, 1990.
  49. T. Manninen, M. L. Linne, and K. Ruohonen, “Developing Itô stochastic differential equation models for neuronal signal transduction pathways,” Comput Biol Chem, vol. 30, pp. 280–291, 2006. View at Google Scholar
  50. K. Burrage and T. Tian, in Advances in Scientific Computing and Applications, Y. Y. Lu and W. Sun, Eds., pp. 82–96, Science Press, 2004.
  51. P. E. Kloeden, E. Platen, and H. Schurz, Numerical Solution of SDE through computer experiments, Springer, 1994.
  52. T. H. Eising, E. D. Conzelman, F. Allgower, E. Bullinger, and P. Scheurich, “Bistability analyses of a caspase activation model for receptor-induced apoptosis,” J Biol Chem, vol. 279, pp. 36892–36897, 2004. View at Google Scholar
  53. E. Z. Bagci, Y. Vodovotz, T. R. Billiar, G. B. Ermentrout, and I. Bahar, “Bistability in apoptosis: Roles of Bax, Bcl-2 and mitochondrial permeability transition pores,” Biophys J, vol. 90, pp. 1546–1559, 2006. View at Google Scholar
  54. X. M. Sun, S. B. Bratton, M. Butterworth, M. MacFarlane, and G. M. Cohen, “Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of x-linked Inhibitor-of-apoptosis protein,” J Biol Chem, vol. 277, pp. 11345–11351, 2002. View at Google Scholar
  55. S. Legewie, N. Blüthgen, and H. Herzel, “Mathematical Modeling Identifies Inhibitors of Apoptosis as Mediators of Positive Feedback and Bistability,” PLoS Comp Biol, vol. 2, pp. 1061–1073, 2006. View at Google Scholar
  56. J. K. Lee, S. Lu, and A. Madhukar, “Real-Time dynamics of Ca2+, Caspase 3/7, and morphological changes in retinal ganglion cell apoptosis under elevated pressure,” PLoS One, vol. 5:e13437, 2010. View at Google Scholar
  57. H. Li, H. Zhu, C. J. Xu, and J. Yuan, “Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis,” Cell, vol. 94, pp. 491–501, 1998. View at Google Scholar
  58. K. Anderson, C. Lutz, F. W. van Delft et al., “Genetic variegation of clonal architecture and propagating cells in leukaemia,” Nature, vol. 469, pp. 356–361, 2011. View at Google Scholar
  59. F. Notta, C. G. Mullighan, J. C. Wang et al., “Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells,” Nature, vol. 469, pp. 362–367, 2011. View at Google Scholar
  60. D. A. Bradbury and N. H. Russel, “Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells,” B J Haemot, vol. 9, pp. 374–379, 1995. View at Google Scholar
  61. A. Porwit-MacDonald, K. Ivory, S. Wilkinson, K. Wheatley, L. Wong, and G. Janossy, “Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia,” Leukemia, vol. 9, pp. 1191–1198, 1995. View at Google Scholar
  62. M. Aguilar-Santelises, M. E. Rottenberg, N. Lewin, H. Mellstedt, and M. Jondal, “Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression,” Int J Cancer, vol. 69, pp. 114–119, 1996. View at Google Scholar
  63. S. Kitada, J. Andersen, S. Akar et al., “Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses,” Blood, vol. 91, pp. 3379–3389, 1998. View at Google Scholar
  64. P. Menendez, A. Vargas, C. Bueno et al., “Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation,” Leukemia, vol. 18, pp. 491–498, 2004. View at Google Scholar
  65. J. Skommer, S. Raychaudhuri, and D. Wlodkowic, “Timing is everything: stochastic origins of cell-to-cell variability in cancer cell death,” Front Biosci, vol. 16, pp. 307–314, 2011. View at Google Scholar
  66. S. Raychaudhuri, “How can we kill cancer cells: Insights from the computational models of apoptosis,” World J Clin Oncol, vol. 1, pp. 24–28, 2010. View at Google Scholar
  67. K. J. Oh, S. Barbuto, K. Pitter, J. Morash, L. D. Walensky, and S. J. Korsmeyer, “A membrane-targeted BID BCL-2 homology 3 peptide Is sufficient for high potency activation of BAX in vitro,” J Biol Chem, vol. 281, pp. 36999–37008, 2006. View at Google Scholar
  68. S. Kurita, J. L. Mott, S. C. Cazanave et al., “Hedgehog Inhibition Promotes a Switch from Type II to Type I Cell Death Receptor Signaling in Cancer Cells,” PLoS One, vol. 6:e18330, 2011. View at Google Scholar
  69. T. Schatton, G. F. Murphy, N. Y. Frank et al., “Identification of cells initiating human melanomas,” Nature, vol. 451, pp. 345–349, 2008. View at Google Scholar
  70. E. Quintana, M. Shackleton, M. S. Sabel, D. R. Fullen, T. M. Johnson, and S. J. Morrison, “Efficient tumour formation by single human melanoma cells,” Nature, vol. 456, pp. 593–598, 2008. View at Google Scholar
  71. H. H. McAdams and A. Arkin, “It's a noisy business! Genetic regulation at the nanomolar scale,” Trends Genet, vol. 15, pp. 65–69, 1999. View at Google Scholar
  72. M. B. Elowitz, A. J. Levine, E. D. Siggia, and P. S. Swain, “Stochastic gene expression in a single cell,” Science, vol. 297, pp. 1183–1186, 2002. View at Google Scholar
  73. A. Sigal, R. Milo, A. Cohen et al., “Variability and memory of protein levels in human cells,” Nature, vol. 444, pp. 643–646, 2006. View at Google Scholar
  74. M. Shackleton, E. Quintana, E. R. Fearon, and S. J. Morrison, “Heterogeneity in cancer: cancer stem cells versus clonal evolution,” Cell, vol. 138, pp. 822–829, 2009. View at Google Scholar
  75. M. Greaves, “Cancer stem cells: Back to Darwin?” Seminars in Cancer Biol, vol. 20, pp. 65–70, 2010. View at Google Scholar
  76. S. D. Girouard and G. F. Murphy, “Melanoma stem cells: not rare, but well done,” Lab Invest, vol. 91, pp. 647–664, 2011. View at Google Scholar
  77. P. Vyas and S. E. Jacobsen, “Clever Leukemic Stem Cells Branch Out,” Cell Stem Cell, vol. 8, pp. 242–244, 2011. View at Google Scholar
  78. T. Borovski, E. De Sousa Melo F, L. Vermeulen, and J. P. Medema, “Cancer Stem Cell Niche: The Place to Be,” Cancer Res, vol. 71, pp. 634–639, 2011. View at Google Scholar
  79. I. Samudio, M. Konopleva, B. Carter, and M. Andreeff, “Apoptosis in leukemias: regulation and therapeutic targeting,” Cancer Treat Res, vol. 145, pp. 197–217, 2010. View at Google Scholar
  80. J. Thompson and A. Winoto, “During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain,” J Exp Med, vol. 205, pp. 1029–1036, 2008. View at Google Scholar